Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | October 07, 2026 | October 09, 2026 |
| Bausch Health Companies Inc.VRX · Entity 4363 | EVP, Company Group Chairman | December 05, 2016 | December 20, 2016 |
| ICON PLCICLR · Entity 3439 | Director | August 10, 2026 | August 12, 2026 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 10, 2022 | January 12, 2022 |
| WOLFSPEED, INC.CREE · Entity 619 | Director | November 05, 2020 | November 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 7,239 |
Reported balance
After 2026-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-07 · Grant · Acquired 7,239 · Balance 7,239 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 10/7/2027. |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.45 · Expires 2036-10-07 | Direct | 17,998 |
Reported balance
After 2026-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-07 · Grant · Acquired 17,998 · Balance 17,998 F3: Shares subject to the stock option award vest in three equal annual installments commencing on 10/7/2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 10/7/2027.
F3: Shares subject to the stock option award vest in three equal annual installments commencing on 10/7/2027.
Bausch Health Companies Inc.
Report date December 05, 2016 · Filed December 20, 2016 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 158,544 |
Reported balance
After 2016-12-05 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-12-05 · Tax withholding · Disposed 6,012 · Balance 158,544 F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Due to administrative error, this number was incorrectly reported in the original Form 4. F2: Represents number of Shares beneficially owned as of the filing date. |
Filing footnotes · ownership attribution and instrument terms
F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Due to administrative error, this number was incorrectly reported in the original Form 4.
F2: Represents number of Shares beneficially owned as of the filing date.
ICON PLC
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 891 |
Ending reported balance
After 2026-08-11 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 1,732 · Balance 1,732 F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. Row 2 · 2026-08-11 · Sale · Disposed 88 · Balance 1,644 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 3 · 2026-08-11 · Sale · Disposed 96 · Balance 1,548 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 4 · 2026-08-11 · Sale · Disposed 590 · Balance 958 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 5 · 2026-08-11 · Sale · Disposed 67 · Balance 891 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-10 · Exercise / conversion · Disposed 1,732 · Balance 0 F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 1,324 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Grant · Acquired 1,324 · Balance 1,324 F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026.
F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.
LISATA THERAPEUTICS, INC.
Report date January 10, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 182,635 |
Reported balance
After 2022-01-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-10 · Grant · Acquired 65,430 · Balance 182,635 F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2: Includes 156,145 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023.
F2: Includes 156,145 unvested restricted stock units.
WOLFSPEED, INC.
Report date November 05, 2020 · Filed November 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 11,274 |
Ending reported balance
After 2020-11-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-11-05 · Exercise / conversion · Acquired 4,000 · Balance 40,522 Row 2 · 2020-11-05 · Sale · Disposed 4,000 · Balance 36,522 Row 3 · 2020-11-05 · Sale · Disposed 25,248 · Balance 11,274 F1: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.40 to $68.70, inclusive. Mrs. Whitaker undertakes to provide Cree, Inc., any security holder of Cree, Inc., or the staff of the Securities Exchange Commission, upon request, information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| NONQUALIFIED STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $57.36 · Expires 2020-12-02 | Direct | 0 |
Reported balance
After 2020-11-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-05 · Exercise / conversion · Disposed 4,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.40 to $68.70, inclusive. Mrs. Whitaker undertakes to provide Cree, Inc., any security holder of Cree, Inc., or the staff of the Securities Exchange Commission, upon request, information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
ORASURE TECHNOLOGIES INC
Report date May 15, 2023 · Filed May 17, 2023
Section 16 reporting ended · disclosed 2023-05-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,840 |
Ending reported balance
After 2023-05-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-15 · Tax withholding · Disposed 4,400 · Balance 26,163 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Row 2 · 2023-05-16 · Tax withholding · Disposed 2,323 · Balance 23,840 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 22:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,998 | $0.00 Strike: $41.45 | $0.00 |
DisclosureSEC source: 0001520262-26-000130 · form4.xml · derivative · entry 2 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,998 Underlying: Ordinary Shares · 17,998 shares Expires 2036-10-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 10/7/2027. Read SEC document |
| October 07, 2026 Filed Oct 9, 2026 22:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 7,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000130 · form4.xml · derivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,239 Underlying: Ordinary Shares · 7,239 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 10/7/2027. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 10/7/2027. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 67 | $165.51 | $11,089.17 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · nonDerivative · entry 5 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 891 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 590 | $164.47 | $97,037.30 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · nonDerivative · entry 4 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 96 | $163.77 | $15,721.92 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · nonDerivative · entry 3 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 88 | $162.72 | $14,319.36 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · nonDerivative · entry 2 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,644 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | GrantRestricted Share Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · derivative · entry 7 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324 Underlying: Ordinary Shares · 1,324 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F8 · derivative.exercise_date: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. F8 · derivative.expiration_date: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. F8 · derivative.underlying: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | Exercise / conversionRestricted Share Units · Derivative | 1,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · derivative · entry 6 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F1 · derivative.exercise_date: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F1 · derivative.expiration_date: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:02 UTC | ICON PLC ICLR · Entity 3439 | Exercise / conversionOrdinary Shares | 1,732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-056328 · wk-form4_1786568543.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F2 · price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:19 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 2,323 | $5.30 | $12,317.71 |
DisclosureSEC source: 0001062993-23-011369 · form4.xml · nonDerivative · entry 2 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,840 F1 · shares: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:19 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 4,400 | $5.62 | $24,706.00 |
DisclosureSEC source: 0001062993-23-011369 · form4.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,163 F1 · shares: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:38 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 20,000 | $5.25 | $105,000.00 |
DisclosureSEC source: 0001062993-22-012923 · form4.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,563 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 15, 2023. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:17 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001593283-22-000002 · wf-form4_164202220799670.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,635 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 156,145 unvested restricted stock units. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:19 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 10,563 | $9.94 | $104,996.22 |
DisclosureSEC source: 0001593968-21-002381 · primary_01.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,563 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on November 10, 2023. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:23 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001593283-21-000005 · wf-form4_161049377878308.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,205 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 117,205 unvested restricted stock units. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:08 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 21,087 | $0.13 | $2,741.31 |
DisclosureSEC source: 0000950138-20-000455 · edgar.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:21 UTC | WOLFSPEED, INC. CREE · Entity 619 | Exercise / conversionNONQUALIFIED STOCK OPTION (RIGHT TO BUY) · Derivative | 4,000 | $0.00 Strike: $57.36 | $0.00 |
DisclosureSEC source: 0000895419-20-000142 · wf-form4_160469766538099.xml · derivative · entry 4 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 4,000 shares Expires 2020-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:21 UTC | WOLFSPEED, INC. CREE · Entity 619 | SaleCOMMON STOCK | 25,248 | $67.87 | $1,713,581.76 |
DisclosureSEC source: 0000895419-20-000142 · wf-form4_160469766538099.xml · nonDerivative · entry 3 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,274 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.40 to $68.70, inclusive. Mrs. Whitaker undertakes to provide Cree, Inc., any security holder of Cree, Inc., or the staff of the Securities Exchange Commission, upon request, information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:21 UTC | WOLFSPEED, INC. CREE · Entity 619 | SaleCOMMON STOCK | 4,000 | $68.35 | $273,400.00 |
DisclosureSEC source: 0000895419-20-000142 · wf-form4_160469766538099.xml · nonDerivative · entry 2 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,522 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:21 UTC | WOLFSPEED, INC. CREE · Entity 619 | Exercise / conversionCOMMON STOCK | 4,000 | $57.36 | $229,440.00 |
DisclosureSEC source: 0000895419-20-000142 · wf-form4_160469766538099.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2020 Filed Nov 4, 2020 00:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 79,470 | $1.51 | $119,999.70 |
DisclosureSEC source: 0001104659-20-121061 · tm2034944d2form4.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,470 F1 · shares: Represents 79,470 shares of restricted stock units granted under the 2018 Equity Incentive Compensation Plan. The shares of restricted stock units will vest in annual installments over a three-year period with the initial vesting on November 1, 2021. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:52 UTC | WOLFSPEED, INC. CREE · Entity 619 | GrantCOMMON STOCK | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000895419-20-000097 · wf-form4_159916629532572.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,522 F1 · kind: Award of restricted stock units vesting in full on September 1, 2021. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:52 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,729 | $2.96 | $25,837.84 |
DisclosureSEC source: 0000950138-20-000267 · edgar.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,087 Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:31 UTC | WOLFSPEED, INC. CREE · Entity 619 | GrantCOMMON STOCK | 3,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000895419-19-000074 · wf-form4_156762907092682.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,870 F1 · kind: Award of restricted stock units vesting in full on September 1, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 11:12 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 19,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000316 · edgar.xml · nonDerivative · entry 2 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,816 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 15, 2019 Filed May 17, 2019 11:12 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,527 | $15.21 | $129,695.67 |
DisclosureSEC source: 0000950138-19-000316 · edgar.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,420 Read SEC document |
| September 01, 2018 Filed Sep 5, 2018 20:33 UTC | WOLFSPEED, INC. CREE · Entity 619 | GrantCOMMON STOCK | 3,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000895419-18-000108 · wf-form4_153617959597608.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,653 F1 · kind: Award of restricted stock units vesting in full on September 1, 2019. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:50 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 18,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000429 · edgar.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,947 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 20:27 UTC | WOLFSPEED, INC. CREE · Entity 619 | GrantCOMMON STOCK | 7,033 | $0.00 | $0.00 |
DisclosureSEC source: 0000895419-17-000082 · wf-form4_150472961580850.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,087 F1 · kind: Award of restricted stock units vesting in full on September 1, 2018. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 21:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 6,505 | $18.00 | $117,090.00 |
DisclosureSEC source: 0001595698-16-000002 · primary_doc.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · EVP, Company Group Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,885 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| December 05, 2016 Filed Dec 20, 2016 23:26 UTC Amendment | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 6,012 | $18.00 | $108,216.00 |
DisclosureSEC source: 0001677301-16-000007 · primary_doc.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · EVP, Company Group Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,544 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Due to administrative error, this number was incorrectly reported in the original Form 4. F2 · balance_after: Represents number of Shares beneficially owned as of the filing date. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:08 UTC | WOLFSPEED, INC. CREE · Entity 619 | GrantCOMMON STOCK | 6,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000895419-16-000185 · wf-form4_147319610705046.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,054 F1 · kind: Award of restricted stock units vesting in full on September 1, 2017. Read SEC document |
| August 02, 2016 Filed Dec 20, 2016 23:04 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 834 | $23.54 | $19,632.36 |
DisclosureSEC source: 0001677301-16-000006 · primary_doc.xml · nonDerivative · entry 1 Whitaker Anne Clem · CIK 0001593283 · EVP, Company Group Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,544 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. F2 · balance_after: Represents number of Shares beneficially owned as of the filing date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.